focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.65
Bid: 35.30
Ask: 36.00
Change: 2.30 (6.97%)
Spread: 0.70 (1.983%)
Open: 32.70
High: 35.30
Low: 35.30
Prev. Close: 33.00
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

25 Mar 2010 07:00

RNS Number : 1442J
China Real Estate Opportunities PLC
25 March 2010
 



 

 

 

China Real Estate Opportunities plc

 

Directors / PDMR Shareholding

 

In accordance with Rule 17 of the AIM Rules, China Real Estate Opportunities plc ("CREO" or the "Company") announces that on 24 March 2010 it was notified by various directors and a significant shareholder, as detailed below, of share purchases made as part of the recent placing by the Company announced on 23 March 2010. Following the completion of the buy back of 1,500,000 shares for cancellation announced on the same day, the issued share capital of the Company is 48,036,004.

 

Richard Barrett, a director of the Company, notified the Company that on 23 March 2010 he purchased 131,510 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.27 per cent of the issued share capital of the Company.

 

Following the share purchase, Richard Barrett has an interest in 8,955,518 ordinary no par value shares representing 18.64 per cent of the issued share capital of the Company.

 

In addition, the Company was notified by Mr Barrett that members of his family purchased 119,000 ordinary no par value shares representing 0.25 per cent of the issued share capital of the Company. Following the share purchase, members of Mr Barrett's family have an interest in 131,891 ordinary no par value shares representing 0.27 per cent of the issued share capital of the Company.

 

Rory Williams, a director of the Company, notified the Company that on 23 March 2010 he purchased 55,000 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.11 per cent of the issued share capital of the Company.

 

Following the share purchase, Mr Williams has an interest in 175,000 ordinary no par value shares representing 0.36 per cent of the issued share capital of the Company.

 

Richard David, a director of the Company, notified the Company that on 23 March 2010 he purchased 17,500 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.04 per cent of the issued share capital of the Company.

 

Following the share purchase, Mr David has an interest in 30,000 ordinary no par value shares representing 0.06 per cent of the issued share capital of the Company.

 

Ray Horney, a director of the Company, notified the Company that on 23 March 2010 Barclays Wealth Trustees (Guernsey) Limited, acting as Trustee of certain trusts under which Mr Horney and / or members of his family are beneficiaries, purchased 75,000 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.16 per cent of the issued share capital of the Company.

 

Following the share purchase, Mr Horney has an interest in 2,825,000 ordinary no par value shares representing 5.88 per cent of the issued share capital of the Company.

 

In addition the Company was notified by Mr Horney that a member of his family purchased 45,000 ordinary no par value shares representing 0.09 per cent of the issued share capital of the Company. This purchase represents the total interest in the Company following the share purchase.

 

On the same day, the Company was notified by John Ronan, a significant shareholder of the Company and a 50 per cent shareholder of Treasury Holdings, that a member of his family purchased 55,000 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.11 per cent and represents their total interest in the Company following the share purchase.

 

 

 

 

 

 

Contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0) 1273 775 225

 

Sarah Moriarty, Investor Relations

Tel: + 353 1 618 9455

 

 

Matrix Corporate Capital LLP

Paul Fincham, Rob Naylor

Tel: + 44 (0) 20 3206 7000

 

 

Davy

Des Carville

Tel: +353 1 679 6363

 

 

Citigate Dewe Rogerson Limited 

Tom Baldock

Tel: 44 (0) 20 7638 9571

 

 

Murray Consultants

Ed Micheau

Tel: + 353 1 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFFDVSISFII
Date   Source Headline
21st Feb 202310:29 amRNSHolding(s) in Company
17th Feb 20232:05 pmRNSSecond Price Monitoring Extn
17th Feb 20232:00 pmRNSPrice Monitoring Extension
17th Feb 202312:10 pmRNSLaunch of Open Offer and Posting of Circular
16th Feb 20236:04 pmRNSResult of Placing and Subscription
16th Feb 20239:05 amRNSSecond Price Monitoring Extn
16th Feb 20239:00 amRNSPrice Monitoring Extension
16th Feb 20237:00 amRNSPlacing and Subscription to raise a minimum £25m
15th Feb 202311:05 amRNSSecond Price Monitoring Extn
15th Feb 202311:00 amRNSPrice Monitoring Extension
30th Jan 20238:51 amRNSAward of Shares under Share Incentive Plan
23rd Jan 202311:47 amEQSCreo Medical (CREO): Progressing on all fronts
18th Jan 20232:05 pmRNSSecond Price Monitoring Extn
18th Jan 20232:00 pmRNSPrice Monitoring Extension
11th Jan 20237:00 amRNSFY 2022 Trading Update
16th Dec 20222:05 pmRNSSecond Price Monitoring Extn
16th Dec 20222:00 pmRNSPrice Monitoring Extension
1st Dec 20222:12 pmRNSHolding(s) in Company
24th Oct 20227:00 amRNSKamaptive Licence and Royalty Agreement with CMR
30th Sep 20227:00 amRNSTotal Voting Rights
23rd Sep 20227:00 amRNSExercise of Options
23rd Sep 20227:00 amRNSExercise of Options
22nd Sep 20227:00 amRNSChris Hancock elected as a Fellow of Royal Academy
9th Sep 20227:00 amRNSHalf-year Report
5th Sep 20227:00 amRNSNotice of Results
31st Aug 20227:00 amRNSTotal Voting Rights
8th Aug 20227:00 amRNSLTIP Awards and PDMR Dealing
4th Aug 20227:00 amRNSExercise of Options
3rd Aug 20227:00 amRNSH1 2022 Trading Update
2nd Aug 20227:00 amRNSAward of Shares under Share Incentive Plan
28th Jun 202212:33 pmRNSResult of AGM
28th Jun 20227:00 amRNSAGM Statement
27th May 20227:00 amRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSPosting of 2021 Annual Report and Accounts
23rd May 20227:01 amRNSFinal Results
23rd May 20227:00 amRNSCollaboration agreement with Intuitive
18th May 20223:22 pmRNSHolding(s) in Company
17th May 20227:00 amRNSNotice of Results
28th Apr 20227:00 amRNSTrading update and notice of results
20th Apr 20227:00 amRNSOpening of Singapore regional hub
5th Apr 20227:00 amRNSCTO wins Technology Innovator of the Year Award
16th Mar 20227:00 amRNSAlbyn Medical earn out update
28th Feb 20227:00 amRNSTotal Voting Rights
7th Feb 20227:00 amRNSPresentation at Growth and Innovation Forum 2022
4th Feb 20227:00 amRNSAward of Shares under Share Incentive Plan
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSTrading update
24th Jan 20227:00 amRNSLicensing & Partnership update
31st Dec 20217:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.